Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B Cell Lymphoma

Explore clinical trials studying Diffuse Large B Cell Lymphoma. Study availability and eligibility vary by location and protocol.

165 public trials 52 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B Cell Lymphoma trial results

Completed

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

NCT03424603

Conditions
B Cells--Tumors, B-cell Lymphoma, Blood Protein Disorders, +26 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arizona Oncology Associates, PC--HOPE Division Tucson, Arizona, United States
  • City of Hope Medical Center Duarte, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
View all 22 locations
View Trial Details
Completed

A Study of ICP-022 in Patients With R/R DLBCL

NCT04438005

Conditions
Diffuse Large B Cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Affiliated Tumor Hospital of Harbin Medical University Haerbin, Heilongjiang, China
  • Jiangsu Province Hospital Nanjing, Jiangsu, China
  • Shengjing Hospital of China Medical University Shenyang, Liaoning, China
View Trial Details
Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

NCT03010982

Conditions
Advanced Solid Tumors, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, +17 more
Locations
  • The Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral, United Kingdom
  • Royal Liverpool and Broadgreen University Hospital Trust Liverpool, United Kingdom
View Trial Details
Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

NCT04858568

Conditions
Burkitt Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +42 more
Locations
  • Bedfordshire Hospitals NHS Foundation Trust Bedford, Bedfordshire, United Kingdom
  • Portsmouth Hospitals University NHS Trust Portsmouth, Hampshire, United Kingdom
  • University Hospital Southampton NHS Foundation Trust Southampton, Hampshire, United Kingdom
  • Wye Valley NHS Trust Hereford, Herefordshire, United Kingdom
View Trial Details
Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +29 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
  • University of Southern California Los Angeles, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 25 locations
View Trial Details
Completed

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

NCT03399513

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • HELIOS Hospital Berlin-Buch Berlin, Germany
  • Hospital Chemnitz Chemnitz, Germany
  • University Hospital Cologne Cologne, Germany
  • University Hospital Göttingen Göttingen, Germany
View Trial Details

Related conditions